Valuation: Chongqing Taiji Industry(Group) Co.,Ltd

Market Cap 9.14B 1.35B 1.18B 1.09B 1B 1.91B 129B 1.94B 13B 5.1B 63.35B 5.06B 4.95B 218B P/E 2026 *
33.2x
P/E 2027 * 17.8x
Enterprise Value 9.14B 1.35B 1.18B 1.09B 1B 1.91B 129B 1.94B 13B 5.1B 63.35B 5.06B 4.95B 218B EV / Sales 2026 *
0.84x
EV / Sales 2027 * 0.8x
Free-Float
59.93%
Yield 2026 *
-
Yield 2027 * -
May. 25 Taiji Industry Gets China Supplementary Nod for Heart Failure Injection MT
May. 14 Chongqing Taiji Industry Gets China Nod for Diabetes Tablets MT
Apr. 29 Chongqing Taiji Industry(Group) Co.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
Mar. 27 Chongqing Taiji Industry(Group) Co.,Ltd Reports Earnings Results for the Full Year Ended December 31, 2025 CI
Feb. 05 Chongqing Taiji Industry(Group) Co.,Ltd agreed to acquire Chongqing Tongjun Pavilion Chinese Medicine Wholesale Co., Ltd. from Chongqing Chinese Medicinal Materials Co., Ltd. and Taiji Group Chongqing Fuling Pharmaceutical Co., Ltd. for CNY 23.4 million. CI
Jan. 20 Yuncheng Taiji Digital Chinese Medicine Co., Ltd. announced that it expects to receive CNY 46.7 million in funding from Chongqing Taiji Industry(Group) Co.,Ltd CI
Dec. 11 Chongqing Taiji Industry(Group) Co.,Ltd(SHSE:600129) dropped from Shanghai Stock Exchange Health Care Sector Index CI
Dec. 10 Chongqing Taiji Industry Subsidiary Goes Under Bankruptcy Administration MT
25-10-24 Chongqing Taiji Industry(Group) Co.,Ltd Reports Earnings Results for the Nine Months Ended September 30, 2025 CI
25-09-23 Tranche Update on Chongqing Taiji Industry(Group) Co.,Ltd's Equity Buyback Plan announced on July 17, 2025. CI
25-09-21 Chongqing Taiji Industry(Group) Co.,Ltd's Equity Buyback announced on July 17, 2025, has closed with 5,472,559 shares, representing 0.98% for CNY 120 million. CI
25-09-10 China Grants Chongqing Taiji Industry Subsidiary Clinical Trial Approval for Diabetes Drug MT
25-08-21 Chongqing Taiji Industry(Group) Co.,Ltd Reports Earnings Results for the Half Year Ended June 30, 2025 CI
1 day+7.73%
1 week+17.67%
Current month+22.18%
1 month+27.34%
3 months+0.67%
6 months-11.05%
Current year-8.14%
1 week 13.42
Extreme 13.42
16.6
1 month 11.56
Extreme 11.56
16.6
Current year 11.56
Extreme 11.56
19.27
1 year 11.56
Extreme 11.56
25.51
3 years 11.56
Extreme 11.56
54.5
5 years 11.56
Extreme 11.56
68.44
10 years 7.81
Extreme 7.81
68.44
Manager TitleAgeSince
Chief Executive Officer 53 2021-05-18
Director of Finance/CFO - 2025-10-24
Investor Relations Contact - -
Director TitleAgeSince
Chairman 53 2024-06-25
Director/Board Member 41 2021-05-18
Director/Board Member 51 2021-05-18
Change 5-day change 1-year change 3-year change Capi.($)
+7.73%+17.67%-23.17%-68.86% 1.35B
-2.33%-2.09%+49.88%+170.51% 1,060B
-0.82%-2.30%+63.79%+62.00% 619B
-0.73%-4.98%+28.91%+82.99% 438B
+0.33%-1.17%+31.07%+27.09% 333B
-0.02%-2.85%+29.15%+45.24% 282B
-3.89%-11.22%+22.81%+27.30% 267B
+0.66%-1.42%-26.59%-37.71% 218B
-0.06%-2.88%+23.07%+62.33% 196B
-3.72%-1.10%+18.41%+70.56% 161B
Average -0.28%-1.34%+21.73%+44.14% 357.53B
Weighted average by Cap. -1.31%-2.95%+36.73%+83.85%

Financials

2026 *2027 *
Net sales 10.88B 1.6B 1.4B 1.29B 1.2B 2.27B 153B 2.31B 15.47B 6.07B 75.38B 6.02B 5.89B 259B 11.4B 1.68B 1.47B 1.36B 1.25B 2.38B 160B 2.42B 16.21B 6.37B 79.03B 6.32B 6.18B 272B
Net income 275M 40.56M 35.48M 32.72M 30.22M 57.35M 3.87B 58.31M 391M 154M 1.91B 152M 149M 6.55B 510M 75.22M 65.79M 60.68M 56.05M 106M 7.17B 108M 725M 285M 3.53B 282M 276M 12.15B
Net Debt - -
Logo Chongqing Taiji Industry(Group) Co.,Ltd
Chongqing Taiji Industry Group Co Ltd is a China-based company that is primarily engaged in the production and sale of Chinese and Western medicines. The Company operates four segments. Pharmaceutical Industry segment mainly produces Chinese patent medicines and Western medicines. Pharmaceutical Business segment mainly includes pharmaceutical distribution and retail. The Company also operates Chinese herbal medicine resource segment and Service and Other segment. The Company's products include digestive system and metabolic drugs, respiratory system drugs, cardiovascular and cerebrovascular drugs, anti-infective drugs, nervous system drugs, anti-tumor and immune regulation drugs, and health products. The Company mainly operates its businesses in the domestic market.
Employees
10,864
Date Price Change Volume
26-07-10 CN¥16.58 +7.73% 52,807,665
26-07-09 CN¥15.39 +2.87% 55,293,956
26-07-08 CN¥14.96 +10.00% 22,555,068
26-07-07 CN¥13.60 -5.03% 15,439,457
26-07-06 CN¥14.32 +1.63% 23,670,239
Trader
-
Investor
Global
-
Quality
ESG MSCI
-

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. 600129 Stock